clinical trial · NCT06835400
Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
Health Hope Pharma·phase3·not yet recruiting·n = 340
Metastatic Breast CancerPaclitaxel CapsuleIV PaclitaxelEncequidar tablet
brief summary
The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).
started
Sep 1, 2025
primary completion
Apr 1, 2028
completion
May 1, 2029
last updated
Jul 11, 2025
official title
An Open-Label, Randomized, Two-stage Study to Determine Dose Optimization, Safety, and Noninferiority of Oral Paclitaxel + Encequidar Compared to IV Paclitaxel in Subjects With HER2 Negative Metastatic Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol